Printer Friendly

Rob Gronkowski Enters CBD Space With Abacus Partnership.

Byline: Andrew Ward

Rob Gronkowski, three-time Super Bowl champion with the NFL's New England Patriots, is the latest athlete to enter the CBD market. The five-time Pro Bowler has agreed to support current and future CBD items from Abacus Health Products, Inc. (CSE:ABCS).

Gronk will be tasked with helping increase brand awareness through marketing and product development.

Awareness efforts are slated to increase in 2020 with what the company calls a "Gronk-inspired" line of nutrition and wellness products. Abacus called Gronkowski an "excellent fit" for the 2020 line, which aims to mark the company's entrance into the ingestible CBD space.

Perry Antelman, Abacus CEO, explained why the NFL vet fit with the brand.

"Gronk's passion for living life to the fullest while maintaining a healthy, natural, and pain-free lifestyle aligns perfectly with the mission of our company," he said.

Gronkowski, who underwent nine surgeries during his NFL career, said, "These products have helped me safely manage pain better than anything else I've tried. I'm inspired to work with the company to introduce new CBD products to the market."

Related Links:

Calvin Johnson's Cannabis Company To Partner With Harvard On CTE, Pain Studies

Eaze Announces CBD Line For Athletes, Partnership With Celtics Legend Paul Pierce

(c) 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

COPYRIGHT 2019 Accretive Capital LLC dba Benzinga.com
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Benzinga.com
Date:Aug 27, 2019
Words:294
Previous Article:Red Robin Poised To Disappoint Street In 2020, BofA Says In Downgrade.
Next Article:Heartland Express Flexes Its Balance Sheet Again With Millis Acquisition.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |